An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
Methods of economic evaluation, especially cost-effectiveness analysis and cost-benefit analysis, are widely used to examine new healthcare technologies. However, few economic evaluations of pharmacogenomics have been conducted, and pharmacogenomic researchers may be unfamiliar with how to review or conduct these analyses. This review provides an overview of the methods of economic evaluation and examples of where they have been applied to pharmacogenomics. We discuss the steps in conducting a cost-effectiveness or cost-benefit analysis, demonstrating these steps using specific examples from the pharmacogenomics literature.
Phillips
Kathryn A
KA
School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 3333 California Street #420 Box 0613, San Francisco, CA 94143, USA. kathryn@itsa.ucsf.edu
Veenstra
David
D
Van Bebber
Stephanie
S
Sakowski
Julie
J
D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics; D006801:Humans; D010597:Pharmacogenetics / Q000191:economics* / Q000379:methods*